Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
about
Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Switching from EPA + DHA (Omeg ...... iovascular Risk: A Case Study.
@en
Switching from EPA + DHA
@nl
type
label
Switching from EPA + DHA (Omeg ...... iovascular Risk: A Case Study.
@en
Switching from EPA + DHA
@nl
prefLabel
Switching from EPA + DHA (Omeg ...... iovascular Risk: A Case Study.
@en
Switching from EPA + DHA
@nl
P2860
P356
P1476
Switching from EPA + DHA (Omeg ...... iovascular Risk: A Case Study.
@en
P2093
James R Crandell
P2860
P304
P356
10.4137/CMC.S38123
P577
2016-07-21T00:00:00Z